Larazotide 500mcg 60 caps.

Larazotide acetate (LA) is a single-chain peptide composed of eight amino acids that functions as a tight junction regulator to restore intestinal barrier integrity. Currently undergoing phase III clinical trials, LA is orally administered to adults with celiac disease as an adjunct therapy to improve intestinal barrier function disrupted by gliadin-induced immune reactions.

Mechanistically, LA is believed to act as a zonulin antagonist, reducing zonulin-induced increases in intestinal permeability. It has been shown to redistribute and rearrange tight junction proteins and actin filaments, aiding in the restoration of the intestinal barrier. More recently, LA has been linked to the inhibition of myosin light chain kinase, which likely reduces tension on actin filaments, promoting tight junction closure. Animal studies, both in rodents (collagen-induced arthritis) and pigs (intestinal ischemic injury), have highlighted the role of LA in regulating tight junctions in conditions beyond celiac disease.